Purdue’s Abuse-Deterrent Hydrocodone: Product, Not Panacea
This article was originally published in The Pink Sheet Daily
Executive Summary
Approving the newly-submitted NDA may relieve some Zohydro-related pressure on FDA, but likely will not end the battle over opioid abuse.